Compass Therapeutics, Inc. (CMPX) — SEC Filings
Compass Therapeutics, Inc. (CMPX) — 31 SEC filings. Latest: 10-Q (May 5, 2026). Includes 11 8-K, 7 10-Q, 3 SC 13G/A.
View Compass Therapeutics, Inc. on SEC EDGAR
Overview
Compass Therapeutics, Inc. (CMPX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 29, 2026: Compass Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 29, 2026, for the period ending December 31, 2025. The company is based in Boston, MA, and its fiscal year ends on December 31st. This filing provides a comprehensive overview of the company's performance and finan
Sentiment Summary
Across 31 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 27 neutral, 1 mixed. The dominant filing sentiment for Compass Therapeutics, Inc. is neutral.
Filing Type Overview
Compass Therapeutics, Inc. (CMPX) has filed 7 10-Q, 11 8-K, 1 ARS, 2 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 2 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (31)
Risk Profile
Risk Assessment: Of CMPX's 22 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$50.773M |
| EPS | -$0.34 |
| Debt-to-Equity | 0.10 |
| Cash Position | $220M |
| Operating Margin | N/A |
| Total Assets | $231.259M |
| Total Debt | $21.646M |
Key Executives
- Sarah E. Michaels
- Dr. Michael J. Ybarra
- Ms. Sarah E. Kelly
- Abigail P. Johnson
Industry Context
Compass Therapeutics operates in the highly competitive biotechnology sector, characterized by long development cycles, significant R&D investment, and high failure rates. Companies in this space often rely on external financing and strategic partnerships to advance their pipelines. The industry is driven by innovation in drug discovery and a complex regulatory approval process.
Top Tags
biotech (8) · sec-filing (4) · Biotechnology (4) · 10-Q (4) · corporate-governance (3) · financials (3) · institutional-ownership (3) · company-update (2) · Oncology (2) · 8-k (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $14.259M | Increased from $10.481M in Q3 2024 |
| Net Loss (9 months 2025) | $50.773M | Increased from $34.342M in 9 months 2024 |
| R&D Expenses (9 months 2025) | $42.297M | Increased from $29.304M in 9 months 2024, a 44% rise |
| Licensing Revenue (9 months 2025) | $0 | Down from $850K in 9 months 2024 |
| Cash, Cash Equivalents & Marketable Securities | $220M | As of Sep 30, 2025, up from $126.722M at Dec 31, 2024 |
| Proceeds from Equity Issuance | $137.999M | For the nine months ended Sep 30, 2025, significantly boosting liquidity |
| Shares Outstanding | 177,862,102 | As of October 30, 2025, indicating dilution from equity raise |
| Liquidity Runway | 2028 | Expected period company can fund operations |
| Revenue | $0 | for the six months ended June 30, 2025, indicating pre-revenue stage |
| General R&D Expenses | $25,000,000 | for the six months ended June 30, 2025, a 25% increase from $20,000,000 in 2024 |
| General & Administrative Expenses | $10,000,000 | for the six months ended June 30, 2025, a 25% increase from $8,000,000 in 2024 |
| CTX-10726 R&D Expenses | $12,000,000 | for the six months ended June 30, 2025, up from $10,000,000 in 2024 |
| Increase in General R&D Expenses | 25% | comparing six months ended June 30, 2025, to 2024 |
| Increase in General & Administrative Expenses | 25% | comparing six months ended June 30, 2025, to 2024 |
| SEC File Number | 001-39696 | Identifies the company's filing history with the SEC. |
Forward-Looking Statements
- {"claim":"Compass Therapeutics' stock price may experience downward pressure due to the reduced institutional ownership.","entity":"Compass Therapeutics, Inc.","targetDate":"short-term","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Compass Therapeutics, Inc. (CMPX)?
Compass Therapeutics, Inc. has 31 recent SEC filings from Jan 2024 to May 2026, including 11 8-K, 7 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CMPX filings?
Across 31 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 27 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Compass Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Compass Therapeutics, Inc. (CMPX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Compass Therapeutics, Inc.?
Key financial highlights from Compass Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CMPX?
The investment thesis for CMPX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Compass Therapeutics, Inc.?
Key executives identified across Compass Therapeutics, Inc.'s filings include Sarah E. Michaels, Dr. Michael J. Ybarra, Ms. Sarah E. Kelly, Abigail P. Johnson.
What are the main risk factors for Compass Therapeutics, Inc. stock?
Of CMPX's 22 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Compass Therapeutics, Inc.?
Recent forward-looking statements from Compass Therapeutics, Inc. include guidance on {"claim":"Compass Therapeutics' stock price may experience downward pressure due to the reduced institutional ownership..